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Background. Tuberculous meningitis (TBM) is a devastating condition. The rapid instigation of appropraite chemotherapy is
vital to reduce morbidity and mortality. However rapid diagnosis remains elusive; smear microscopy has extremely low
sensitivity on cerebrospinal fluid (CSF) in most laboratories and PCR requires expertise with advanced infrastructure and has
sensitivity of only around 60% under optimal conditions. Neither technique allows for the microbiological isolation of M.
tuberculosis and subsequent drug susceptibility testing. We evaluated the recently developed microscopic observation drug
susceptibility (MODS) assay format for speed and accuracy in diagnosing TBM. Methodology/Principal Findings. Two
hundred and thirty consecutive CSF samples collected from 156 patients clinically suspected of TBM on presentation at
a tertiary referal hospital in Vietnam were enrolled into the study over a five month period and tested by Ziehl-Neelsen (ZN)
smear, MODS, Mycobacterial growth Indicator tube (MGIT) and Lowenstein-Jensen (LJ) culture. Sixty-one samples were from
patients already on TB therapy for .1day and 19 samples were excluded due to untraceable patient records. One hundred and
fifty samples from 137 newly presenting patients remained. Forty-two percent (n=57/137) of patients were deemed to have
TBM by clinical diagnostic and microbiological criteria (excluding MODS). Sensitivity by patient against clinical gold standard
for ZN smear, MODS MGIT and LJ were 52.6%, 64.9%, 70.2% and 70.2%, respectively. Specificity of all microbiological
techniques was 100%. Positive and negative predictive values for MODS were 100% and 78.7%, respectively for HIV infected
patients and 100% and 82.1% for HIV negative patients. The median time to positive was 6 days (interquartile range 5–7),
significantly faster than MGIT at 15.5 days (interquartile range 12–24), and LJ at 24 days (interquartile range 18–35 days)
(P,0.01). Conclusions. We have shown MODS to be a sensitive, rapid technique for the diagnosis of TBM with high sensitivity,
ease of performance and low cost (0.53 USD/sample).
Citation: Caws M, Ha DTM, Torok E, Campbell J, Thu DDA, et al (2007) Evaluation of the MODS Culture Technique for the Diagnosis of Tuberculous
Meningitis. PLoS ONE 2(11): e1173. doi:10.1371/journal.pone.0001173
INTRODUCTION
Tuberculous meningitis (TBM) results in death or severe disability
in as many as two thirds of patients [1]. The early diagnosis and
instigation of chemotherapy is crucial to a successful outcome. In
the absence of identification of drug resistance and institution of
second line drug therapy, multi-drug resistant (MDR) TBM is
always fatal [2]. However TBM diagnosis is difficult: the clinical
presentation is diverse, rapid tests insensitive and the differential
diagnosis is broad.
Three options are currently available for the rapid diagnosis of
TBM: Ziehl-Neelsen (ZN) smear, molecular assays and diagnostic
algorithms. In experienced hands, using large CSF volumes
(.6 mls) and meticulous examination of slides (at least 30 minutes)
the sensitivity of smear can exceed 60% [3,4]. It is cheap and
simple to perform. However, large volumes of CSF are rarely
submitted to the laboratory, particularly from paediatric patients.
Furthermore, in routine laboratories it is often not feasible to
devote adequate time to examine a single specimen. Molecular
techniques such as PCR assays require highly trained technicians,
rigorous quality control to guard against contamination, are
expensive and are not more sensitive than meticulous smear [5,6].
Diagnostic algorithms based on simple clinical and laboratory
features can be sensitive and specific [7] but require further
evaluation, particularly in HIV-infected patients and children . ZN
smear and diagnostic algorithms do not allow for the microbio-
logical isolation of Mycobacterium tuberculosis (M. tuberculosis)o r
identification of drug resistance. By contrast, PCR can potentially
combine identification and detection of drug resistance in
one test.
Commercial rapid liquid culture techniques have greatly
reduced turn around times for the isolation and drug susceptibility
testing of mycobacteria [8]. They are, however, too expensive for
routine use by most national tuberculosis control programs in
developing nations and tend to be used on limited numbers of
specimens in national reference laboratories.
Microscopic observation drug susceptibility assay (MODS) is
a technique for the cheap, rapid identification of drug resistant M.
tuberculosis through direct drug susceptibility testing (DST) in liquid
culture [9–11]. Equipment requirements are minimal: a level 2
Biological Safety Cabinet and inverse light microscope. It has low
cross-contamination rates and is suitable for use in high-burden
settings [9].
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as done with MODS on sputum specimens, will yield a high
sensitivity due to the low numbers of bacilli in the primary specimen.
Furthermore, inthe comparative evaluation of diagnostic techniques
for TBM, isolates are often seen to be positive by smear or PCR but
negativebythemoresensitive culture;thisisthought to be due to the
clumping of bacilli in aliquots of a sample [5]. These two factors are
likely to lead to many uninterpretable and false positive results in
direct susceptibility testing. We have therefore evaluated MODS as
a technique for the rapid identification of M. tuberculosis in the CSF in
comparison with MGIT and LJ culture against a clinical gold
standard. Following primary isolation, samples can be inoculated for
further DST, either by MODS, molecular techniques or conven-
tional phenotypic DST, where available.
RESULTS
Two hundred and thirty samples were collected from 156 patients
(figure 1). Sixty-one samples were from patients who were already
on treatment (.1 day) for HIV associated TBM and were
therefore analysed separately. Clinical data was not available for
nineteen samples and these were therefore excluded from further
analysis. One follow-up sample from a patient on treatment for 2
days had a contaminated MODS culture. This sample was positive
by LJ and MGIT.
One hundred and fifty samples from 137 newly presenting
patients remained. Fifty-seven (42%, n=57/137) patients were
deemed to have TBM by clinical diagnostic and microbiological
criteria, excluding MODS (table 1). Of these patients, 30 were ZN
smear positive, 27 of which were also positive by MODS. A
further 27 were diagnosed with TBM clinically or by microbio-
logical culture; ten of these were positive by MODS. For the nine
patients without microbilogical confirmation of TBM, no other
pathogen was isolated from the CSF, the CSF biochemistry was
consistent with TBM and there was a response to TBM therapy or
evidence of concurrent pulmonary TB.
Eighty patients did not fulfil the diagnostic criteria for TBM and
were negative by ZN smear, MODS, LJ, MGIT. Eighty-eight
patients (n=88/137, 64.2%) were HIV-infected. A summary of
the patient data is presented in tables 1 (TBM patients) and 2
(other diagnoses).
When analysed by patient, sensitivity of MODS was 90.0% [95%
C.I 79.2–100] (n=27/30), 80.4% [95% C.I. 68.4–91.6] (n=37/46)
and 64.9% [95% C.I 52.7–77.3] (n=37/57) against smear, culture
and clinical criteria respectively (table 3). With a clinical gold
standard the sensitivity of smear was 53% [95% C.I. 40.1–65.9]
(n=30/57) and of both culture techniques, LJ or MGIT 70.2%
[95% C.I. 58.0–82.0] (n=40/57). There was 91.9% agreement
between the MODS and MGIT tests, Kappa=0.801. For MODS
and LJ, agreement was 89.0%, kappa=0.728; for MGIT and LJ
there was 91.2% agreement, kappa=0.788. Sensitivity and
specificity data is summarised in table 4.
Specificity of all techniques was 100% (n=80/80). The
sensitivity and specificity of MODS was 58.8% [95% C.I. 35.7–
82.3] (n=10/17) and 100% (n=32/32) in HIV-uninfected
patients and 67.5% [95% C.I. 53.5–82.5] (n=27/40) and 100%
(n=48/48), in HIV-infected patients. The positive and negative
predictive values were 100% and 78.7% in HIV-infected patients
and 100% and 80.0% in HIV negative patients, respectively.
Figure 1. Flowchart of patients presenting to Hospital for Tropical Diseases with suspected TBM during the study showing results for standard
microbiological investigations (MGIT/LJ/ZN smear) and MODS on CSF samples.
doi:10.1371/journal.pone.0001173.g001
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PLoS ONE | www.plosone.org 2 November 2007 | Issue 11 | e1173Table 1. Features of 57 newly presenting patients with a final diagnosis of TBM.
..................................................................................................................................................
patient
number
HIV
status
Final
diagnosis
MODS
(days) ZN-smear
MGIT
(days)
LJ
(days)
CSF white
cell count
(cells/ml)
CSF
protein
(g/L)
CSF
glucose
(mmol/L)
CSF/blood
glucose
ratio supplementary information
6 neg TBM Neg. Neg. Neg. Neg. 200 1.9 3.3 0.36 PTB, smear neg
10 neg TBM +.(4) +. +(10) + (14) 1450 1.2 0.8 0.5 miliary PTB
12 + TBM Neg. Neg. Neg. + (65) 34 1.7 3 0.55
13 + TBM Neg. Neg. Neg. Neg. 1 ,1
14 + TBM +.(6) +. +(17) +(17) 275 1.1 3.4 0.63
15 + TBM +.(6) +. Neg. +(13) 110 1.8 5.5 0.18 PTB, died
16 + TBM +.(3) +. Neg. +(13) 160 2.4 0.5 0.10 PTB
18 neg TBM +.(14) neg Neg. +(57) 270 1.6 0.5 0.10
23 + TBM +.(7) +. +(18) +(18) 116 1.4 1.9 0.31 PTB, dilated ventricles on CT
30 + TBM +.(6) +. +(50) Neg. 62 1.3 2.2 0.43
31 + TBM Neg. Neg. Neg. Neg. 0.6 1.5 0.38 PTB
33 + TBM Neg. Neg. Neg. Neg. 60 1.6 1.7 0.33
36 + TBM Neg. Neg. Neg. Neg. 1.6 1.5 0.39
38 + TBM +.(6) +. +(35) +(20) 695 1.4 2.7 0.38
40 neg TBM +.(4) +. +(32) +(18) 750 1.3 2 0.36
43 + TBM +.(21) Neg. +(29) Neg. 102 1.5 1.8 0.30
44 neg TBM +.(7) Neg. +(29) +(37) 650 1.34 1.6 0.2 PTB
46 neg TBM +.(10) Neg. +(17) +(40) 480 ,1 miliary TB . Abnormal CT
52 neg TBM +.(6) Neg. +(14) +(31) 60 1.7 ,0.5
53 neg TBM Neg. Neg. Neg. Neg. 224 2.1 2.1 0.40
55 + TBM +.(7) +. +(14) + (14) 675 1.6 2 0.5 miliary TB
66 + TBM Neg. +. Neg. +(25) 40 2.2 1.3 0.22 miliary TB, died
68 + TBM +.(7) Neg. +(16) +(30) 685 0.95 2.5 0.33
78 + TBM +.(4) +. +(8) +(14) 2980 2.4 1.3 0.30 CT consistent with TBM, PTB
88 neg TBM Neg. Neg. +(21) +(55) 1.5 2 0.40
89 + TBM +.(30) Neg. +(21) +(55) 510 1.7 1.6 0.29
92 + TBM Neg. +. Neg. +(70) 2.3 1.2 0.23
96 + TBM Neg. Neg. +(31) +(55) 293 1.2 2.4 0.49 CT consistent with TBM,
105 + TBM +.(4) +. +(35) +(35) 350 1.6 ,0.5
106 + TBM +.(6) +. +(17) +(21) 218 2.1 ,0.5
127 + TBM Neg. Neg. +(32) +(32) 2010 1.2 2.2 0.42 CT consistent with TBM,
129 neg TBM +.(7) +. Neg. Neg. 1.5
131 + TBM +.(8) Neg. +(13) +(21) 590 1.4 1.6 0.42 miliary TB
136 + TBM +.(6) +. +(13) +(17) 375 1.2 ,0.5
138 + TBM +.(5) +. +(8) +(26) 180 1.3 1.4 0.18 CT consistent with TBM, PTB
140 + TBM Neg. Neg. +(28) +(63) 10 0.6 2.3 0.38 fungi neg
141 neg TBM Neg. Neg. Neg. Neg. 210 1 2.8 0.64
143 + TBM +.(4) +. +(7) +(28) 3950 1.4 1.3 0.33 CT consistent with TBM
144 neg TBM Neg. Neg. Neg. Neg. 0.8 1.6 0.30
146 + TBM +.(4) Neg. +(15) +(28) 149 0.32 1.6 0.22
148 + TBM +.(7) +. +(14) +(21) 1475 1.2 ,0.5
152 neg TBM +.(6) Neg. +(14) +(21) 238 0.8 ,0.5
157 + TBM +.(7) +. +(11) +(18) 1290 0.5 2.5 0.36 CT consistent with TBM, PTB,
completed treatment of
tuberculous lymphadenitis
previously
159 neg TBM Neg. Neg. Neg. Neg. 1.2 2.8 0.68
166 + TBM Neg. +. Neg. Neg. 140 0.5 2.5 0.36 CT consistent with TBM, PTB
167 + TBM +.(6) +. +(4) +(17) 340 1.3 2 0.45 CT consistent with TBM
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PLoS ONE | www.plosone.org 3 November 2007 | Issue 11 | e1173When analysed by sample against a clinical gold standard, the
sensitivity and specificity of MODS for newly presenting patients
was 65.1% [95% C.I. 53.2–76.8] (n=41/63), and 100% (n=87/
87) respectively. The sensitivites by sample for smear, LJ and
MGIT were 52.4% [95% C.I. 39.7–64.3] (n=33/63), 68.3%
[95% C.I. 56.4–79.6] (n=43/63) and 73.0% [95% C.I. 62.0–
84.0] (n=46/63), respectively. The specificity of all methods was
100%. In 96 samples from HIV-infected patients, the sensitivity
was 68.9% [95% C.I. 55.5–82.5] (n=31/45) and specificity 100%
(n=51/51). In 54 samples from HIV-uninfected patients the
sensitivity was 55.6% [95% C.I. 42.7–69.3] (n=10/18) and
specificity was 100% (n=36/36).
The median time to detection of MODS positive cultures
(n=41) from newly presenting patients was 6 days (interquartile
range 5–7 days). Ninety percent of samples (n=37/41) were
positive in #10 days. The median time to positive for MGIT
(n=46) and LJ cultures (n=43) was 15.5 days (interquartile range
12–24 days) and 24 (interquartile range 18–35), respectively.
MODS was significantly faster than MGIT and LJ (P,0.01),
(Figure 2).
The mean CSF sample volume was 4.6 mls (range 1–14 mls).
For MODS positive samples the average volume was 5.2 mls
(range1–14 mls) and for MODS negative samples 4.4 mls (range
1–13 mls).
Of 61 CSF samples from 27 patients on TBM therapy for
between 2 days and 9 months, 16 were positive by one of the four
methods. Seven samples were positive by MODS. Eight samples
were positive by smear, 10 by MGIT and 9 by LJ (table 5).
Among the 80 patients not diagnosed with TBM, 34 had a final
diagnosis of fungal menigitis, 6 viral meningitis, 14 bacterial
meningitis and 3 toxoplasmosis. The majority of diagnoses in the
remaining cases remained uncertain (table 2).
Costs
The cost per test of MODS for diagnosis was 0.53 USD per
sample.
DISCUSSION
MODS is a sensitive, rapid technique for the diagnosis of TBM.
Although MGIT showed a slightly higher sensitivity in this study,
the difference was not significant (65% vs. 73%, P=0.335) and
MODS is significantly faster (median 6 days vs. 15.5 days,
P,0.01). A smaller volume of deposit was innoculated into the
MODS culture than the MGIT culture (100 ml versus 250 ml) and
this is likely to account for the slightly lower sensitivity.
The median time to a positive MODS culture shown here is
slightly faster than the median detection time of 7 days for isolation
of M. tuberculosis from sputum samples in a large evaluation of
MODS in Peru [11]. This shorter time to detection is surprising
due to the paucibacillary nature of CSF samples and may be
because the NALC-NAOH decontamination of sputa samples
reduces viability of the TB bacilli- prior decontamination is not
required for CSF samples. Moore et al. have previously shown that
the bacillary load of a sample (measured by bacilli/100fields on
smear) has negligible impact on time-to culture positivity by
MODS [11]. It may be possible to reduce time to detection with
the introduction of confirmatory biochemical or molecular tests for
early confirmation of M. tuberculosis. Studies to evaluate these
strategies are underway at our hospital.
We have previously shown serial positive mycobacterial cultures
from patients on antituberculous therapy [2,5]. In this study, 4/5
(80%) follow-up patients were positive after 2 days of treatment
with antituberculous chemotherapy and between 3–6 days 5/9
(55.5%) patients were positive. However, after 7 days of
chemotherapy positive cultures were rare; four samples (18.2%)
were positive between 7 and 28 days of therapy and after 29 days
only 2/24 (8.3%) were positive. Growth of the follow-up samples
from HIV-positive patients in MODS culture was impaired, with
short cords and slow growth; the clinical significance of these
results is unclear. The utility of MODS for the follow-up of TBM
patients on treatment, particularly as an early indicator of drug
resistance requires further investigation.
The high sensitivity reported here will only be replicated if
relatively large volumes of CSF are used. We have previously
shown that the microbiological identification of M. tuberculosis in
the CSF is highly volume-dependent [3]. The average volume in
this study was 4.6 mls, with the deposit divided into aliquots for 4
tests. The MODS plate was inoculated with only 100 ml of CSF
deposit, whereas 250 ml each was used for MGIT and LJ culture.
This may account for the slightly higher sensitivity of MGIT
(70.2% vs 64.9%).
patient
number
HIV
status
Final
diagnosis
MODS
(days) ZN-smear
MGIT
(days)
LJ
(days)
CSF white
cell count
(cells/ml)
CSF
protein
(g/L)
CSF
glucose
(mmol/L)
CSF/blood
glucose
ratio supplementary information
176 + TBM +.(6) +. +(13) +(16) 142 1.5 2 0.33
179 + TBM Neg. Neg. +(13) Neg. 505 1.2 1.8 0.63
181 + TBM Neg. Neg. +(12) +(27) 284 1.3 3 0.6 lymph node AFB smear (+)
182 + TBM +.(5) +. +(12) +(22) 1.5 ,0.5
194 + TBM +.(5) +. +(13) Neg. 2460 1.6 1.3 0.17 Encephalitis on CT
197 + TBM +.(7) +. +(34) Neg. 233 1.7 1.5 0.34
200 neg TBM +.(6) +. +(15) +(18) 410 not done 1.4 0.22 CT consistent with TBM, PTB
201 neg TBM Neg. Neg. +(12) +(15) 1.2 2.1 0.28
204 neg TBM +.(8) +. +(11) +(30) 1065 1.2 3.2 0.51
207 + TBM +.(7) +. +(24) +(24) 544 1.6 2.1 0.29 pneumonia on CXR
211 + TBM +(5) +. +(22) Neg. 644 0.9 3.1 0.62
CXR=chest X-ray, CT=computerised tomography of the brain, TBM=tuberculous meningitis, +=positive, neg=negative, AFB=Acid fast bacilli, PTB=pulmonary
tuberculosis.
doi:10.1371/journal.pone.0001173.t001
Table 1. cont.
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PLoS ONE | www.plosone.org 4 November 2007 | Issue 11 | e1173Cryptococcal meningitis is the second most common cause of
meningitis among HIV-infected patients at our hospital (figure 3).
Twenty-two percent (35/156) of patients here were diagnosed with
fungal meningitis, all but one of whom were HIV-infected.
Twenty-six of these were confirmed as cryptoccal meningitis
through CSF India Ink smear or cryptococcal latex agglutination
antigen test (Remel Inc., Lenexa, Kansas, USA). Dual infections
with Cryptococcus neoformans and M. tuberculosis are occasionally seen
in HIV–infected patients at our hospital; thus a diagnosis of
cryptococcal meningitis does not exclude the possibility of TBM.
This study was performed in a tertiary referral hospital by
a dedicated technician who was able to examine each plate daily
for growth. In routine laboratories, optimal examination schedules
would need to be established to optimise sensitivity while
minimising workload. Our experience suggests a four, seven, ten
and fourteen day schedule would be appropriate for CSF
specimens. Moore et al. recently showed that rates of contamina-
tion in a high-volume laboratory are not greater using MODS
than other culture techniques for the isolation M. tuberculosis [9],
a finding supported by our study which showed only one
contaminated culture in 230 samples (0.4%).
All the cultures isolated in MODS were confirmed to be M.
tuberculosis by spoligotyping (data not shown). Isolation of atypical
mycbacteria from CSF is extremely rare and optimal treatment
has never been determined in clinical trials. Classical cording of M.
tuberculosis in MODS is thought to be specific for identification in
the hands of an experienced microscopist, however a rapid
confirmatory test such as a nitrate strip test may be appropriate.
This issue requires evaluation in a larger study.
In summary, MODS is an extremely promising technique for
the rapid diagnosis of TBM, isolating M. tuberculosis from CSF
within 10 days in the majority of cases at low cost (0.53 USD per
sample). It is cheap, simple, sensitive, specific and applicable in
low-technology laboratories. Its main advantage is the cheap,
rapid microbiological isolation of M. tuberculosis from CSF and the
potential to perform DST within a clinically useful timeframe.
MATERIALS AND METHODS
Patient recruitment and sample collection
CSF samples were collected from consecutive patients (aged over
14 years) with clinically suspected TBM (defined as a combination
of nuchal rigidity and CSF abnormalities) presenting to the
Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
between June 1st and November 1st 2006. TBM was defined as
‘‘definite’’ if acid-fast bacilli were seen in the CSF. It was defined
as ‘‘probable’’ in patients with one or more of the following:
suspected active pulmonary tuberculosis on chest radiography;
acid-fast bacilli found in any specimen other than the cerebrospi-
nal fluid; clinical evidence of other extra-pulmonary tuberculosis;
radiological features of TBM on computed tomography (CT) scan
or magnetic resonance imaging (MRI) of the brain. TBM was
defined as ‘‘possible’’ in patients with at least four of the following:
a history of tuberculosis, predominance of lymphocytes in the
cerebrospinal fluid, illness duration of more than five days, a ratio
of cerebrospinal fluid glucose to plasma glucose of less than 0.5,
altered consciousness, yellow cerebrospinal fluid, or focal neuro-
logical signs. All patients who fulfilled the above diagnostic criteria
were treated for TBM with standard antituberculous chemother-
apy and adjunctive dexamethasone. All patients were tested for
antibodies to human immunodeficiency virus (HIV) as part of
routine care. Those who were found to be HIV-infected were
screened for inclusion in an ongoing randomised double-blind
placebo-controlled trial of immediate versus deferred antiretroviral
Figure 2. Cumulative percentage of positive cultures by day for MODS, MGIT and LJ culture.
doi:10.1371/journal.pone.0001173.g002
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In addition to routine biochemical tests, all CSF samples were also
examined by Gram-stain and India ink stain, and cultured on blood,
chocolate and sabouraud dextrose agar, to exclude bacterial and
cryptococcal meningitis respectively. All samples included in this
study weretaken aspartof routine clinical careand the study did not
involve anychange to routine patient careand thereforeconsent and
ethical review was not deemed necessary.
The volume of each CSF sample was recorded, the sample
centrifuged at 3,000g for 15 mins, the supernatant removed and
the deposit aliquoted into 4 parts. ZN smear, LJ and MGIT
culture were performed on each specimen according to methods
previously described [3].
MODS
MODS testing was performed by a technician who was unaware
of the clinical diagnosis, smear and other culture results. The
method was performed as described in Moore et al. [10] with 2
minor modifications; 48 well plates were used in place of 24 and
a plate sealer (Biorad optical tape, Biorad, Hercules CA, USA) was
used to avoid evaporation and cross-contamination in the plate.
MODS media was prepared with 5.9 g Middlebrook 7H9 broth
(Difco, Sparks, MD), 3.1 mls glycerol and 1.25 g bacto casitone
(Difco, Sparks, MD) in 880 mls sterile distilled water. The media
was autoclaved and stored in 22 ml aliquots at 4uC. Each new
batch was tested for sterility by incubating one aliquot at 37uC for
1 week. One MODS plate was set up each day with the addition of
2.5 mls OADC (Becton Dickinson) and 500 ml PANTA antibiotic
(Becton Dickinson). Nine hundred ml media was aliquoted to each
well and 100 ml CSF deposit added. One positive control (H37Rv)
and one negative control well (sterile distilled water) were
inoculated each day. Plates were examined daily (on weekdays)
for evidence of growth (figure 4).
Statistics
The sensitivity, specificity, positive predictive value and negative
predictive value for MODS were determined and compared with
ZN smear and LJ and MGIT culture, using clinical diagnosis
(instigation of anti-tuberculous chemotherapy) as the gold-
standard. Time to result for the three culture methods was
compared using Wilcoxon signed rank test. Samples were
excluded where patient medical records were not available for
analysis.
Table 3. Results of MODS for 137 patients presenting with
suspected TBM by final diagnosis.
......................................................................
clinical diagnosis TBM Non-TBM Total
MODS positive 37 0 37
MODS negative 20 80 100
Total 57 80 137
doi:10.1371/journal.pone.0001173.t003
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Table 4. Sensitivity of all techniques analysed by sample (n=63), patient (n=57) and HIV status. Specificity of all techniques in all
cases was 100%.
..................................................................................................................................................
Technique [% sensitivity (no. positive samples)]
Group smear MODS MGIT LJ
Analysis by sample (n=63) 52.4% (33) 65.1% (41) 73% (43) 68.3% (43)
Analysis by patient (n=57) 53.0% (30) 64.9% (37) 70.2% (40) 70.2% (40)
HIV negative patients only (n=17) 29.4% (5) 58.8% (10) 58.8% (10) 64.7% (11)
HIV positive patients only (n=40) 62.5% (25) 67.5% (27) 75% (30) 72.5% (29)
doi:10.1371/journal.pone.0001173.t004
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Figure 3. Cryptococcus neoformans in MODS plate at 6400
magnification with inverted microscope.
doi:10.1371/journal.pone.0001173.g003
Figure 4. M. tuberculosis characteristic cording in MODS plate at
6400 magnification with inverted microscope.
doi:10.1371/journal.pone.0001173.g004
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PLoS ONE | www.plosone.org 9 November 2007 | Issue 11 | e1173Table 5. Summary of 61 follow-up samples from 27 HIV-positive patients with HIV associated TBM on .7 days TB therapy*.
..................................................................................................................................................
patient
treatment duration at
sample date (days) CSF volume (mls) MODS (DAYS) smear MGIT (DAYS) LJ (DAYS) supplementary information
101 84 4 NEG NEG NEG NEG
113 210 2 NEG NEG NEG NEG
12 7 3 NEG NEG NEG NEG
12 28 3 NEG NEG NEG NEG
12 49 3 NEG NEG NEG NEG
12 84 2 NEG NEG NEG NEG
123 6 6 NEG + NEG NEG DIED
127 5 4 NEG NEG NEG + (28)
127 28 3 NEG NEG NEG NEG
131 6 4 NEG NEG + (14) + (21)
131 28 1 NEG NEG +(15) NEG
143 2 2 cx ++ (13) + (23)
15 6 5 NEG NEG NEG NEG DIED
150 2 9 + (10) ++ (14) + (21)
150 5 2 NEG NEG NEG NEG
150 28 2 +(7) + NEG NEG
165 42 3 NEG NEG NEG NEG
165 56 1 NEG NEG NEG NEG
166 3 4 NEG + NEG NEG
166 7 3 NEG NEG NEG NEG
166 28 2 NEG NEG NEG NEG
167 7 2 NEG NEG NEG NEG
167 28 1 NEG NEG NEG NEG
17 28 2 NEG NEG NEG NEG
194 2 3 NEG + NEG NEG
194 6 3 NEG NEG NEG NEG
202 84 3 NEG NEG NEG NEG
207 2 9 + (7) ++ (20) +(20)
207 7 7 NEG NEG NEG NEG
211 7 2 NEG NEG NEG NEG
23 2 4 NEG NEG NEG NEG
23 28 3 NEG NEG NEG NEG
23 56 3 NEG NEG NEG NEG
25 70 1 NEG NEG NEG NEG
25 168 2 NEG NEG +(12) NEG
28 252 5 NEG NEG NEG NEG DIED
30 28 1 NEG NEG NEG NEG
30 42 2 NEG NEG NEG NEG
30 70 3 + (8) NEG +(17) +(21)
35 28 5 NEG NEG NEG NEG
41 49 2 NEG NEG NEG NEG DIED
41 70 3 NEG NEG NEG NEG DIED
55 21 3 NEG NEG NEG NEG
55 70 7 NEG NEG NEG NEG
58 56 3 NEG NEG NEG NEG
58 84 5 NEG NEG NEG NEG
63 56 2 NEG NEG NEG NEG
66 6 3 NEG NEG NEG NEG DIED
66 28 4 + (16) NEG +(19) NEG DIED
.
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The costs of the MODS assay were calculated based upon locally
purchased reagents, where possible. It was assumed 40 samples
were inoculated per plate, with 1 H37Rv positive control per plate
and 1 negative control per row. Labour, capital equipment costs
and maintenance costs were not included in the calculations which
represent only the price of consumables. An inverse microscope is
approximately 2,000 USD. An exchange rate of 16,000 Vietnam-
ese Dong (VND) was used to convert costs to US dollars.
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